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PharmGKB is a leading resource of high quality pharmacogenomics data that provides information about
how genetic variations modulate an individual’s response to drugs. PharmGKB contains information
about genetic variations, pharmacokinetic and pharmacodynamic pathways, and the effect of variations
on drug-related phenotypes. These relationships are represented using very general terms, however, and
the precise semantic relationships among drugs, and diseases are not often captured. In this paper we
develop a protocol to detect and disambiguate general clinical associations between drugs and diseases
using more precise annotation terms from other data sources. PharmGKB provides very detailed clinical
associations between genetic variants and drug response, including genotype-speciﬁc drug dosing guide-
lines, and this procedure will be adding information about drug–disease relationships not found in
PharmGKB. The availability of more detailed data will help investigators to conduct more precise queries,
such as ﬁnding particular diseases caused or treated by a speciﬁc drug.
We ﬁrst mapped drugs extracted from PharmGKB drug–disease relationships to those in the National
Drug File Reference Terminology (NDF-RT) and to Structured Product Labels (SPLs). Speciﬁcally, we
retrieved drug and disease role relationships describing and deﬁning concepts according to their relation-
ships with other concepts from NDF-RT. We also used the NCBO (National Center for Biomedical Ontol-
ogy) annotator to annotate disease terms from the free text extracted from ﬁve SPL sections (indication,
contraindication, ADE, precaution, and warning). Finally, we used the detailed drug and disease relation-
ship information from NDF-RT and the SPLs to annotate and disambiguate the more general PharmGKB
drug and disease associations.
 2013 Elsevier Inc. All rights reserved.1. Introduction
The Pharmacogenomics Knowledge Base (PharmGKB [1]) is a
publicly available internet resource for pharmacogenomics data
and knowledge that provides information about genes involved
in modulating the response to drugs. PharmGKB includes data
about genetic variations, pharmacokinetic and pharmacodynamic
pathways, and the effects of genetic variations on drug-related
phenotypes. PharmGKB also provides integrated knowledge
including relationships among genes, drugs, and diseases. The
importance of this resource is widely recognized, and it has been
used in several investigations. For example, Pathak et al. [2]
investigated pharmacodynamics (PDs) and pharmacokinetics
(PKs) relationships between drugs and diseases in PharmGKB,
and compared them with the drug–disease relationships in
NDF-RT. Theobald et al. [3] extracted the relationships between
drugs, disease and genes from PubMed guided by the relationships
from PharmGKB.While PharmGKB collects, encodes, and disseminates
knowledge about the impact of human genetic variations on drug
response [4], the detailed semantic relationships between drugs
and diseases are not often captured during the curation process.
For example, PharmGKB contains a generic relationship between
the drug donepezil (PA449394) and the disease dementia
(PA443853), but no detailed information about that relationship
is provided. The availability of more precisely annotated drug
and disease associations would be invaluable to the research com-
munity, especially for drug repositioning studies.
Detailed information about drug–disease relationships would
also be valuable to studies that focus on Adverse Drug Events
(ADEs). Vilar et al. [5] combined data from the US Food and Drug
Administration’s (FDA) Adverse Event Reporting System (AERS)
with similarity measures of molecular structure, a process that
achieved signiﬁcant improvement in precision in computationally
detecting ADEs. Benton et al. [6] conducted a study to identify
potential ADEs by using medical message boards and online
resources. Jiang et al. [7] developed ADEpedia by using ADE infor-
mation from SPLs to create a RDF triple store. Each of these studies
improve our ability to detect ADEs, which is a crucial step for
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annotation of drug and disease associations from PharmGKB that is
described in this paper adds signiﬁcant value to existing resources,
thereby facilitating studies like those mentioned above.
The overall goal of this study is to enrich the drug and disease
associations in PharmGKB with more detailed semantic relation-
ships. We present a method to disambiguate the clinical associa-
tions between drugs and diseases in PharmGKB. We utilized the
Veterans Affairs National Drug File Reference Terminology (NDF-
RT [8]) and DailyMed Structured Product Labeling (SPL [9]) as the
sources of detailed information about drug–disease associations,
and demonstrated how existing data sources can be used to
semantically enrich each other.2. Background
We annotated drug and disease relationships from PharmGKB
using publicly available data sources. Each source is described be-
low, along with rationale for its use in this study.2.1. PharmGKB
PharmGKB contains genomic, phenotype and clinical informa-
tion collected from pharmacogenomics studies. More speciﬁcally,
PharmGKB provides information regarding variant annotations,
drug-centered pathway, pharmacogene summaries, clinical anno-
tations, pharmacogenomics based drug-dosing guidelines, drug la-
bels with pharmacogenomics information. PharmGKB also
provides to registered research network members tools to browse,
query, download, submit, edit and process the information [4].2.2. Veterans Affairs National Drug File Reference Terminology
(NDF-RT)
NDF-RT is produced and maintained by the U.S. Department of
Veterans Affairs (VA). It is used for modeling drug characteristics
including ingredients, chemical structure, dose form, physiologic
effect, mechanism of action, pharmacokinetics, and related dis-
eases [10]. NDF-RT concepts are grouped into several general cat-
egories, including drug and disease. The drug category includes
VA classiﬁcations of medications, generic ingredient preparations
used in medications, and orderable (clinical) VA drug products.
The disease category includes pathophysiologic data as well as cer-
tain non-disease physiologic states that are treated, prevented, or
diagnosed by an ingredient or drug product. In addition, the dis-
ease category may also describe contraindications.
Although PharmGKB provides mappings with ATC (Anatomical
Therapeutic Chemical) and DrugBank, we used NDF-RT in this
study for several reasons: (1) ATC is a proprietary terminology;
(2) neither ATC nor DrugBank provide information about drug
and disease associations; (3) NDF-RT has been integrated into
RxNorm, which is speciﬁed by U.S. Meaningful Use regulations;
(4) NDF-RT is updated weekly.2.3. Structured Product Labeling (SPL)
The SPL standard has been adopted by the FDA for exchanging
information about drugs and drug ingredients, including dosage,
strength, usage, and known ADEs [10]. SPL documents contain
structured sections that in turn contain unstructured content that
comprise the product label (including all text, tables and ﬁgures).
SPL deﬁnes the content of human prescription drug labeling in
an XML format that are organized by section headings; 76 section
headings have been deﬁned and coded by LOINC [11].SPLs were used in this study as a data source that compliments
NDF-RT. Other studies have used this resource in a similar manner,
which allows us to extend our current work with other resources
and applications.
2.4. National Center for Biomedical Ontology (NCBO) annotator
The NCBO annotator is an ontology-based web service for anno-
tating textual biomedical data with concepts from more than 200
ontologies, which are part of two important repositories of bio-
medical ontologies and terminologies: the UMLS Metathesaurus
and NCBO BioPortal [12]. The NCBO annotator provides the capa-
bility for detecting and annotating disease terms within the SPL
free text used in this study.3. Methods
Data sets were retrieved from the PharmGKB July 16th, 2011
snapshot. Of the 24,227 relations in the dataset, 2698 drug–disease
relationships were extracted, including 363 relationships between
a drug class and a disease. The drug class-disease relationships
were excluded from the analysis since NDF-RT only provides rela-
tionships between individual drugs and diseases. Therefore, 2335
drug–disease relationships from PharmGKB were annotated in this
study. These relationships included 579 distinct drugs (called
‘‘PharmGKB drug’’ in this report), and 444 distinct diseases. The
annotation process is illustrated in Fig. 1.
We mapped PharmGKB drugs to records in the NDF-RT and SPL
data sets, then used the disease information obtained from these
two resources to more precisely annotate the PharmGKB drug
–disease relationships. The annotation workﬂow is shown in
Fig. 2. The steps involved are described in the following sections.
3.1. NDF-RT extraction
NDF-RT provides role relationships that describe and deﬁne
concepts according to their relationships with other concepts. Each
role has a domain (the kind of concept whose deﬁnition may use
the role) and a range (the kind of concept to which the role can re-
fer) [10]. In this study, we focused on the role relationships be-
tween NDF-RT concepts that are ‘‘Generic Ingredients or
Combinations’’ or ‘‘Disease’’, as shown in Table 1.
The NDF-RT API [13] was used to retrieve information for the
579 PharmGKB drugs, using the drug name as an input parameter
(Fig. 1). The query results included the NDF-RT drug identiﬁer
(NUI) and its corresponding role relationships (Table 1).
To ensure the accuracy of the mappings between PharmGKB
and NDF-RT, we manually reviewed all mappings in which the
NDF-RT concept names did not exactly match the PharmGKB drug
names. The review process conﬁrmed that all non-exact mappings
were due only to differences in spelling, use of synonymous terms,
and differences in drug representation format, and therefore they
were retained for further analysis.
3.2. SPL extraction
SPLs provide high quality information for marketed drugs,
which includes generic names, ingredients, dosage forms, routes
of administration, and usage of the drug. While the SPLs are only
semi-structured, they are a valuable resource that can be used to
enrich the annotation for PharmGKB drug and disease pairs, and
therefore we utilized them in this study.
The SPL data set was downloaded from DailyMed on 11/4/2011,
and stored in a local database. We extracted the disease informa-
tion from the ﬁve SPL sections listed in Table 2 as detailed below,
Fig. 1. PharmGKB drug–disease annotation process diagram.
Fig. 2. Annotation workﬂow.
Table 1
Deﬁnition of role relationships from NDF-RT.
Role Deﬁnition
may_treat Therapeutic use or indication of a generic ingredient
preparation or drug
may_prevent Preventative use or indication of a generic ingredient
preparation or drug
may_diagnose Diagnostic use or indication of a generic ingredient
preparation or drug
induces Therapeutic effect or state caused by a generic ingredient
Preparation or drug
CI_with Therapeutic or co-morbid contraindication of a generic
ingredient preparation or drug
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3.3. SPL disease information extraction
For each PharmGKB drug, SPL documents were located in our
local database and disease information was extracted from the sec-
tions listed in Table 2. To identify SPLs for a given drug, the RxCUI
was used as an intermediary identiﬁer to retrieve the SPL setId
from the RxNav REST API [14]. Two separate calls to the API were
required: one to obtain the RxCUI for a given PharmGKB drug name
and another to retrieve the SPL setId for a given RxCUI. Once SPL
documents were identiﬁed using the setId, unstructured text was
extracted using SAXParser. The text was submitted to the NCBO
annotator to obtain disease terms.
3.4. Annotating SPL free text
Using the NCBO annotator, the free text from the ﬁve SPL sec-
tions listed in Table 2 was annotated with terms from standardizedterminologies. To increase the speciﬁcity of the annotations, the
annotated concepts were ﬁltered by UMLS semantic type [14];
terms that mapped to one of the disease-related types listed in
Table 3 were retained for further evaluation. For example, the
phrase ‘‘ARICEPT is indicated for the treatment of dementia of
the Alzheimers type’’ was obtained from the’’INDICATION’’ section
Table 2
SPL sections used in this study.
SPL sections LOINC code
Indication and usage 34067-9
Adverse reactions 34084-4
Precautions 42232-9
Warnings 34071-1
Contraindications 34070-3
Table 3
UMLS sematic types used in this study.
UMLS semantic
types
Names
T047 Disease or syndrome
T191 Neoplastic process
T046 Pathologic function
T033 Finding
T184 Sign or symptom
T048 Mental or behavioral
dysfunction
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cessfully identiﬁed the term ‘‘dementia’’ and mapped it to a term
from the OMIM ontology; that term has a semantic type of ‘‘Dis-
ease or Syndrome’’ (semantic type T047). Similar results were ob-
tained for all text extracted from the SPL documents.
Due to the conceptual overlap among sections (see Table 2), it is
not uncommon to ﬁnd statements related to indications and con-
traindications in the same section. For example, the statement
‘‘VICOPROFEN is not indicated for the treatment of such conditions
as osteoarthritis or rheumatoid arthritis’’ expresses a contraindica-
tion as a negated indication. Automatically detecting and annotat-
ing this type of statement may be possible using a tuned natural
language processing (NLP) tool, but since a validated NLP system
was not available we employed a hybrid approach. Speciﬁcally,
we utilized OpenNLP [15] to split the content from the
‘‘INDICATION’’ section into individual sentences and used a list of
negative words (e.g., ‘‘not’’, ‘‘neither’’, ‘‘unable’’) to identify poten-
tial contraindication statements. If a negative word was found in a
sentence, we ﬂagged that sentence for manual review. This ap-
proach, while fairly primitive, was an efﬁcient method for identify-
ing statements that may generate inaccurate annotations.
3.5. Annotating PharmGKB drug–disease associations
The results from the previous steps yielded precise semantic
relationships between drugs and diseases, which were used to dis-
ambiguate the general associations listed in PharmGKB. We com-
pared each PharmGKB drug–disease relationship to annotation
data for the corresponding drug–disease pairs from NDF-RT and
SPL (see Fig. 2). Known synonyms for drug and disease terms were
used to maximize the number of successful matches. In cases
where matches were not found by term identiﬁer for diseases, sub-
string matching was employed. Fig. 4 shows an example of Phar-
mGKB drug–disease annotation results.
4. Results
4.1. Annotation results from NDF-RT
The NDF-RT API was used to obtain mappings between 579
PharmGKB drug names and NDF-RT unique identiﬁers (NUIs).
Mappings were obtained for 464 PharmGKB drug names, whereas
115 PharmGKB drugs failed to map to NDF-RT concepts (the reason
for the failure will be addressed in the Discussion section). In most
cases where mappings were obtained, the NDF-RT concept name
exactly matched the PharmGKB drug name. Manual review was
conducted for the 14 non-exact matches that were returned (Table
4). All 14 matches were found to be correct after accounting for dif-
ferences in spelling, use of synonymous terms, and drug represen-
tation format. Therefore, those 14 mappings were included in the
subsequent analysis.
Using the RxNav API, disease (role) information was obtained
for each of the 464 distinct PhramGKB drugs for which NUIs were
available. Unfortunately, not all NDF-RT concepts had associated
disease information (e.g., hydrocortisone) and 84 drugs were ex-
cluded from further analysis for this reason. The remaining 380
distinct drugs were related to 672 distinct diseases through 3148drug–disease role pairs. Table 5 shows the number of relations
by NDF-RT role type (deﬁned in Table 1). For example, there are
1703 relations that describe drugs that ‘‘may_treat’’ a given dis-
ease. The 1703 ‘‘may treat’’ relations consisted of 368 distinct
drugs and 510 distinct diseases.4.2. Annotation results from SPL
To create drug–disease associations from the SPL resource, the
section names were used to deﬁne the type of association between
the drug referenced by the SPL document and the disease term(s)
that were found within the section. These associations were then
used to disambiguate the drug–disease relationships in PharmGKB.4.2.1. RxCUI generation
To identify SPLs for a given drug, the RxCUI was used as an
intermediary identiﬁer to retrieve the SPL setId from the RxNav
REST API. Of the 579 PharmGKB drug names, 459 were mapped
to 17,426 RxCUIs (14,726 unique RxCUIs) (mappings were not
found for 120 drugs using this method). Another 18 distinct Phar-
mGKB drugs resulted in 808 non-exact mappings between Phar-
mGKB and RxNorm (see, examples in Table 6). By manually
reviewing the literature (see the ‘‘Reference’’ column in Table 6),
we veriﬁed that the 808 non-exact mappings were caused by syn-
onymous representations used by PharmGKB and RxNorm. There-
fore, those mappings were included in the subsequent analysis.4.2.2. SPL extraction
The 14,726 distinct RxCUIs generated in the above step were
used to retrieve SPL setIds via the RxNAV API. A total of 12,549 set-
Ids were returned, and text from the sections listed in Table 2 was
extracted from each SPL document, which was then annotated
with disease terms. The extraction and annotation results for each
section are listed in Table 7. In this table, we list unique numbers of
SPL sections, annotated drug–disease pairs (e.g. drug-indication,
drug-ADE, etc.), relevant drugs, and relevant diseases.4.3. Evaluation of NCBO annotation
To evaluate the accuracy of the NCBO annotation, the annota-
tions from a random set of 60 PharmGKB drugs were manually re-
viewed. From this set of 60 PharmGKB drugs, 98 SPL labels were
obtained. We manually reviewed the free text from the indications
section of these SPLs and compared them to the 1023 correspond-
ing annotations from the NCBO annotator. The evaluation results
are listed in Table 8. The false positives were instances where
non-disease terms such as, ‘‘pressure’’ or ‘‘stomach’’ were mapped
to a term that was classiﬁed as one of the disease-related semantic
types (Table 3). In addition, 13 false negatives were found that
were not identiﬁed by NCBO annotator, such as ‘‘Prophylaxis of Or-
gan Rejection in Renal Transplantation’’.
Fig. 3. An example of NCBO annotator output in XML.
Fig. 4. Example of PharmGKB drug–disease annotation result.
Table 4
Non-exact string matches between PharmGKB drug and NDF-RT.
PharmGKB drug name NDF-RT concept name RxNorm name
Abacavir Avacavir Abacavir
Carmustine Camustine Carmustine
Colchicine Colchicine Colchicine
Valproic acid Divalproex Valproic Acid
Copper sulfate Cupric sulfate Copper sulfate
Copper sulfate Copper (as cupric sulfate) Copper sulfate
Copper sulfate Cupric sulfate, anhydrous Copper sulfate
Ethanol Alcohol Ethanol
Ethanol Alcohol, ethyl Ethanol
Drotrecogin alfa Drotrecogin alfa (activated) Drotrecogin alfa
Epoetin alfa Epoetin alfa, recombinant Epoetin alfa
Estradiol Estradiol 17-beta ESTRADIOL
Certolizumab pegol Certolizumab Certolizumab pegol
Beta carotene Carotene, beta Beta carotene
Table 5
Mapping PharmGKB drugs to NDF-RT.
Role type # of Relations # of Distinct drugs # of Distinct diseases
CI_With 1230 375 241
induces 19 10 13
may_diagnose 6 5 6
may_prevent 190 98 74
may_treat 1703 368 510
Total 3148 380 672
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A total 80 statements from SPL sections were ﬂagged for review
due to the presence of a negative word. Manual review of eachstatement conﬁrmed that 20 of them were true positives (an
expression of a contraindication). The remaining 60 statements
were false positives (e.g., ‘‘children under 2 years of age, do not
use, consult a doctor’’), which were re-annotated and included in
the subsequent analysis for the drug and disease pairs.
4.5. PharmGKB drug–disease relationships annotation
Using the annotations and mappings from the NDF-RT and SPL
data sets, 1,222 distinct PharmGKB drug–disease relationships
Table 6
Examples of non-exact mapping in drug name between PharmGKB and RxNorm.
PharmGKB drug
name
RxNorm concept name Reference
Glibenclamide Glyburide 1.25 mg
oral tablet [micronase]
Glibenclamide (INN), also
known as glyburide (USAN), is
an antidiabetic drug in a class of
medications known as
sulfonylureas, closely related to
sulfa drugs [20]
Fenoﬁbrate Fenoﬁbric acid 35 mg
oral tablet [ﬁbricor]
Fenoﬁbric acid, an active form of
fenoﬁbrate, increases
apolipoprotein A-I-mediated
high-density lipoprotein
biogenesis by enhancing
transcription of ATP-binding
cassette transporter A1 gene in a
liver X receptor-dependent
manner [21]
Cyanocobalamin Vitamin b 12 0.1 mg/
ml injectable solution
[crystal b-12]
Cyanocobalamin is an especially
common vitamer of the vitamin
B12 family [22]
Table 9
Annotation results for PharmGKB drug–disease relationships
by NDF-RT.
Role/section types # Unique drug–disease pairs
may_diagnose 1
may_prevent 54
may_treat 313
CI_With 61
induces 1
Table 10
Annotation results for PharmGKB drug–disease relationships
by SPL.
Role/section types # Unique drug–disease pairs
Indication 620
ADE 833
Warnings 722
Precautions 564
Contraindications 188
Table 8
Evaluation results for NCBO annotation.
#
Indications
True
positive
False
positive
False
negative
Precision Recall F-
measure
1023 816 194 13 80.8% 98.4% 88.7%
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out of the 2,335 relationships that were present in PharmGKB at
the time of this study. These relationships included 394 distinct
drugs and 275 distinct diseases (Tables 9 and 10). These results
will be made publicly available and will be contributed to
PharmGKB.
5. Discussion
In this study, we employed two different approaches for
extracting detailed semantic annotations for drug–disease pairs
from the NDF-RT and SPL resources, and subsequently used them
to disambiguate the general drug–disease relationships in Phar-
mGKB. For NDF-RT, the mapping process was very straightforward
due to two aspects: the content was available in a structured for-
mat (XML) and its existing drug–disease associations reduced the
need for additional curation. While this approach was relatively
simple computationally, NDF-RT yielded fewer drug–disease asso-
ciations than the SPL dataset (Tables 9 and 10).
The SPL resource required the extraction and annotation of drug
and disease relations from free text. To accomplish this, we ex-
plored an approach that utilized OpenNLP and the NCBO annotator
to extract and annotate disease information, and we used manual
annotation to evaluate the accuracy of the annotations. While the
development of this process was not the main focus of this work,
it was a necessary step toward accomplishing the primary goal of
obtaining semantically rich drug–disease associations. The SPL re-
source would be much more valuable to the research community if
the information was available in a structured and codiﬁed format.
We support ongoing efforts to mine, annotate, and connect infor-
mation contained in SPLs with that in other resources. An example
of these efforts is the LinkedSPLs project [16], which provides links
between SPLs and terminologies such as DrugBank and RxNorm.
Overall, 52% (1222 of 2335) of PharmGKB drug–disease rela-
tionships were successfully disambiguated using one or more
precise relationships extracted from the NDF-RT and SPL resources.Table 7
SPL extraction and annotation results.
Indications Adverse reactio
# Unique sections 4678 5179
# Unique drugs 430 430
# Unique diseases 3688 8850
# Unique drug–disease relations 17,350 145,391This project not only provides tangible results in the form of de-
tailed drug–disease associations, but also demonstrates how re-
sources such as NDF-RT and SPL can be used to add value to
already high-quality human-curated repositories such as Phar-
mGKB. In most cases when annotations were available from both
NDF-RT and SPL, the annotations were consistent with each other.
For example, NDF-RT deﬁnes anemia as a contraindication for the
administration of hydroxyurea (i.e., the role type of the association
is ‘‘CI_with’’). Similarly, ‘‘anemia’’ is present within the ‘‘CONTRA-
INDICATION’’ section of an SPL for hydroxyurea. Some annotations
from these two resources were different, however. For example,
NDF-RT deﬁnes an association between norepinephrine and hypo-
tension with the role type ‘‘CI_with’’ (i.e., specifying a contraindica-
tion), whereas the opposite relationship (‘‘INDICATION’’) was
extracted from SPL. When this was observed, the conﬂict was re-
solved by consulting DailyMed, which in this example supported
the latter association (an indication).
A signiﬁcant fraction (130 of 579, or 22%) of the drug names
listed in PharmGKB could not be mapped to NDF-RT and/or
RxNorm. Speciﬁcally, 115 PharmGKB drugs could not be mapped
to a NUI and 103 failed to map to an RxCUI. Many failed mappings
were due to PharmGKB’s use of chemical IUPAC names, which
were not included in NDF-RT or RxNorm. For example, the Phar-
mGKB drug entry ‘‘3-beta-hydroxy-5-androsten-17-one’’ failed to
map to the terminologies using the methods described in this pro-
ject. However, a synonym for this compound is ‘‘Dehydroepian-
drosterone’’, which has a NUI (N0000148779). To address this
issue, additional data sources such as PubChem [17] and DrugBank
[18], which contain IUPAC names, could be used to identify addi-ns Contraindications Precautions Warnings
3481 4400 4932
401 334 427
1917 5632 5510
10,278 54,544 60,570
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used to query for this information; DrugBank does not have an API
but the data could be downloaded to a local repository and queried
directly.
PharmGKB also contains some entries for compounds that are
not used for treatment, and therefore are not included in NDF-RT
or RxNorm. For example, PharmGKB associates ‘‘calcein’’ with four
diseases (‘‘Leukemia’’, ‘‘Leukemia, Myeloid’’, ‘‘Leukemia, Myeloid,
Acute’’ and ‘‘neoplasms’’), but this compound is a cytoplasmic ﬂuo-
rescent dye used for diagnosis rather than for pharmaceutical
treatment [19].
Finally, we failed to ﬁnd mappings for some drug–disease asso-
ciations due to the use of general disease terms within PharmGKB.
For example, the PharmGKB dataset used for this study included
terms such as ‘‘Transplantation’’ (N = 22), ‘‘Drug Toxicity’’
(N = 93), and ‘‘Neoplasms’’ (N = 108). Other terms, such as ‘‘Death’’
(N = 55) were also included as diseases. While some of these terms
might be included as an upper-level term in the NDF-RT or
NxNorm terminologies, it is possible that other ontologies might
be needed to express these concepts.
6. Conclusion
We present a method for disambiguating PharmGKB drug and
disease associations that utilizes the NDF-RT and SPL resources. This
work focused on individual drugs; future work could include the
annotation of drug classes using concepts from NDF-RT and/or ATC.
While the results of this study yielded meaningful results that
can be of immediate use to the research community, more work
is required to maximize the potential of these data sources. For in-
stance, automatic annotation methods could be improved but ide-
ally the primary data sources (e.g., SPL) would contain structured
and codiﬁed content that is computationally accessible. Also,
new terms could be added to existing terminologies and ontologies
but perhaps more important are the additions of cross-references
and links among those resources. Both of these approaches will
add value to these data sets, facilitating drug-repositioning studies
and efforts to detect ADEs.
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